A phase III study of comparing FOLFOX plus /-bevacizumab with FOLFOX plus /-bevacizumab plus high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.

被引：0
|
作者：
Wang, Feng
Xiao, Jian
Zhang, Yan-Qiao
Yuan, Xianglin
Fang, Weijia
Wang, Wei
Hu, Xiaohua
Zhuang, Zhixiang
Zhou, Fuxiang
Ying, Jieer
Yuan, Ying
Guo, Zeng-qing
Wu, XiangYuan
Zou, Qing-Feng
He, Ming-ming
Guo, Ying
Chen, Shuang-Zhen
Xu, Rui-hua
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China
[3] Harbin Tumor Hosp, Dept Gastrointestinal Med Oncol, Harbin, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China
[5] First Affiliated Hosp Zhejiang Prov, Hangzhou, Peoples R China
[6] First Peoples Hosp Foshan, Guangzhou, Foshan, Peoples R China
[7] Guangxi Med Univ, Affiliated Canc Hosp, Nanning, Guangxi, Peoples R China
[8] SooChow Univ, Affiliated Hosp 2, Dept Med Oncol, Suzhou, Peoples R China
[9] Wuhan Univ, Zhongnan Hosp, Hubei Canc Clin Study Ctr, Wuhan, Peoples R China
[10] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[11] Fujian Med Univ, Canc Hosp, Canc Bioimmunotherapy Ctr, Fuzhou, Peoples R China
[12] Fujian Canc Hosp, Fuzhou, Peoples R China
[13] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Peoples R China
[14] Guangzhou Med Univ, Canc Ctr, Guangzhou, Peoples R China
[15] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4115
引用
收藏
页数：2
相关论文
共 50 条
  • [21] FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study
    Iwamoto, S.
    Takahashi, T.
    Tamagawa, H.
    Nakamura, M.
    Munemoto, Y.
    Kato, T.
    Hata, T.
    Denda, T.
    Morita, Y.
    Inukai, M.
    Kunieda, K.
    Nagata, N.
    Kurachi, K.
    Ina, K.
    Ooshiro, M.
    Shimoyama, T.
    Baba, H.
    Oba, K.
    Sakamoto, J.
    Mishima, H.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (07) : 1427 - 1433
  • [22] Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).
    Wainberg, Zev A.
    Boccia, Ralph V.
    Strickler, John H.
    Moehler, Markus H.
    Sirard, Cynthia A.
    Walsh, Erin K.
    Parker, Elizabeth C.
    Lee, Keun-Wook
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS275 - TPS275
  • [23] FOLFOX-6 PLUS IMATINIB, BEVACIZUMAB AND CETUXIMAB IN ADVANCED UNTREATED COLORECTAL CANCER
    Andretta, V
    Bennicelli, E.
    Pessino, A.
    Caprioni, F.
    Decian, F.
    Di Benedetto, M.
    Sobrero, A.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 113 - 113
  • [24] CHARTA: FOLFOX/Bevacizumab plus /- Irinotecan in advanced colorectal cancer - long term outcome
    Meinert, F.
    Schmoll, H. -J
    Garlipp, B.
    Junghanss, C.
    Leithaeuser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. -G
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C., V
    Hildebrandt, B.
    Steighardt, J.
    Cygon, F.
    Stein, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 245 - 245
  • [25] Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial
    Tyagi, Preeta
    Grothey, Axel
    [J]. CLINICAL COLORECTAL CANCER, 2006, 6 (04) : 261 - 264
  • [26] FOLFOX/bevacizumab plus /- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome
    Schmoll, H.
    Garlipp, B.
    Junghanss, C.
    Vogel, A.
    Kaiser, U.
    Florschuetz, A.
    Kanzler, S.
    Hannig, C.
    Meinert, F.
    Cygon, F.
    Stein, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [27] Modified FOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab beyond first progression in advanced colorectal cancer: CCOG-0801 study.
    Ishigure, Kiyoshi
    Nakayama, Goro
    Uehara, Keisuke
    Yokoyama, Hiroyuki
    Ishiyama, Akiharu
    Eguchi, Takehiko
    Tsuboi, Kenji
    Ando, Yuichi
    Kodera, Yasuhiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [28] Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study
    Bendell, Johanna C.
    Tournigand, Christophe
    Swieboda-Sadlej, Anna
    Barone, Carlo
    Wainberg, Zev A.
    Kim, Jong Gwang
    Pericay, Carles
    Pastorelli, Davide
    Tarazi, Jamal
    Rosbrook, Brad
    Bloom, Joanna
    Ricart, Alejandro D.
    Kim, Sinil
    Sobrero, Alberto F.
    [J]. CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 239 - 247
  • [29] Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment
    Tsuji, Akihito
    Yoshino, Takayuki
    Yamanaka, Takeharu
    Bando, Hideaki
    Satake, Hironaga
    Yamazaki, Kentaro
    Taniguchi, Hiroya
    Oki, Eiji
    Kotaka, Masahito
    Oba, Koji
    Miyata, Yoshinori
    Muro, Kei
    Komatsu, Yoshito
    Baba, Hideo
    Kato, Takeshi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [30] A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Hochster, Howard S.
    Hart, Lowell L.
    Firdaus, Irfan
    Mace, Joseph Ronald
    McFarlane, Joshua Jemison
    Kozloff, Mark
    Catenacci, Daniel Virgil Thomas
    Hsu, Jessie J.
    Hack, Stephen Paul
    Shames, David S.
    Phan, See-Chun
    Cohn, Allen Lee
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345